Science Explorer Back to mapMap
Discussion
Institution · Alexion Pharma (Switzerland)

Most cited papers from Alexion Pharma (Switzerland)

Alexion Pharma (Switzerland)

What are the most cited papers from Alexion Pharma (Switzerland)?

The most cited paper from Alexion Pharma (Switzerland) is "Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial" (Christopher T. Ritchlin et al., 2014), with 664 citations. Next come "Predominant role for C5b-9 in renal ischemia/reperfusion injury" (466) and "Genetic Variants in C5 and Poor Response to Eculizumab" (417).

Showing 50 of 60 papers. Every paper with more than 84 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial Christopher T. Ritchlin et al. · Annals of the Rheumatic Diseases Open access 30 Jan 2014 664
2 Predominant role for C5b-9 in renal ischemia/reperfusion injury Wuding Zhou, Conrad A. Farrar, Katsushige Abe et al. · Journal of Clinical Investigation Open access 15 May 2000 466
3 Genetic Variants in C5 and Poor Response to Eculizumab Jun‐ichi Nishimura et al. · New England Journal of Medicine Open access 12 Feb 2014 417
4 Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion Antti Väkevä, Azin Agah, Scott A. Rollins et al. · Circulation 9 Jun 1998 400
5 Development and Application of Cell-Based Biosensors Joseph Jewell Pancrazio, James Whelan, David A. Borkholder et al. · Annals of Biomedical Engineering Nov 1999 390
6 Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv Thomas C. Thomas, Scott A. Rollins, Russell P. Rother et al. · Molecular Immunology Dec 1996 364
7 Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Yijun Wang, Scott A. Rollins, Joseph A. Madri et al. · Proceedings of the National Academy of Sciences Open access 12 Sep 1995 360
8 Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. William L. Fodor, Bethany L. Williams, Louis A. Matis et al. · Proceedings of the National Academy of Sciences Open access 8 Nov 1994 347
9 Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Yijun Wang, Qiongzheng Hu, Joseph A. Madri et al. · Proceedings of the National Academy of Sciences Open access 6 Aug 1996 341
10 The neural basis of psychedelic action Alex C. Kwan, David E. Olson, Katrin H. Preller et al. · Nature Neuroscience Open access 24 Oct 2022 317
11 Review of Electronic Patient-Reported Outcomes Systems Used in Cancer Clinical Care Roxanne E. Jensen, Claire Frances Snyder, Amy P. Abernethy et al. · Journal of Oncology Practice Open access Jul 2014 316
12 Diagnosis of genetic diseases in seriously ill children by rapid whole-genome sequencing and automated phenotyping and interpretation Michelle M. Clark et al. · Science Translational Medicine Open access 24 Apr 2019 307
13 Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass Jane C.K. Fitch, Scott A. Rollins, Louis A. Matis et al. · Circulation Open access 21 Dec 1999 285
14 Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid Pablo García‐Pavía, Fabian aus dem Siepen, Erwan Donal et al. · New England Journal of Medicine Open access 20 May 2023 246
15 Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis Tuan Vu, Andreas Meisel, Renato Mantegazza et al. · NEJM Evidence 26 Apr 2022 241
16 Mannose-Binding Lectin Is a Regulator of Inflammation That Accompanies Myocardial Ischemia and Reperfusion Injury Mary C. Walsh, Todd Bourcier, Kazue Takahashi et al. · The Journal of Immunology Jul 2005 240
17 Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis Gèrard Socié, Marie‐Pierre Caby‐Tosi, Jing L. Marantz et al. · British Journal of Haematology Open access 15 Feb 2019 235
18 FERONIA controls pectin- and nitric oxide-mediated male–female interaction Qiaohong Duan, Ming-Che James Liu, Daniel Kita et al. · Nature 18 Mar 2020 218
19 Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder Sean Joseph Pittock, Michael Harry Barnett, Jeffrey L. Bennett et al. · Annals of Neurology Open access 3 Mar 2023 211
20 Assignment of the membrane attachment, DNA binding, and transcriptional activation domains of sterol regulatory element-binding protein-1 (SREBP-1). Ryuichiro Sato, Jinlin Yang, Xiaodong Wang et al. · Journal of Biological Chemistry Open access Jun 1994 198
21 Gastrointestinal Ischemia-Reperfusion Injury Is Lectin Complement Pathway Dependent without Involving C1q Melanie L. Hart, Kathleen Ceonzo, Lisa A. Shaffer et al. · The Journal of Immunology May 2005 195
22 Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization Anita V. Hill, Russell P. Rother, Lisa Arnold et al. · Haematologica Open access 9 Feb 2010 195
23 A Role for Complement in Antibody-Mediated Inflammation: C5-Deficient DBA/1 Mice Are Resistant to Collagen-Induced Arthritis Yi Wang, Jane Kristan, Liming Hao et al. · The Journal of Immunology Open access Apr 2000 195
24 Terminal Complement Blockade With Pexelizumab During Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass Edward D. Verrier, Stanton Keith Shernan, Kenneth M. Taylor et al. · JAMA 18 May 2004 191
25 Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome Franz S. Schaefer et al. · Kidney International Open access 18 Jun 2018 180
26 CD200 Expression on Tumor Cells Suppresses Antitumor Immunity: New Approaches to Cancer Immunotherapy Anke Kretz-Rommel, Fenghua Qin, Naveen K. Dakappagari et al. · The Journal of Immunology Open access May 2007 179
27 In vitro and in vivo modifications of recombinant and human IgG antibodies Hongcheng Liu, Gomathinayagam Ponniah, Hui‐Min Zhang et al. · mAbs Open access 14 Jul 2014 173
28 The Detroit Community-Academic Urban Research Center: Development, Implementation, and Evaluation Barbara A. Israel, Richard L. Lichtenstein, Paula M. Lantz et al. · Journal of Public Health Management and Practice 2001 160
29 Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors Truman John Milling et al. · Circulation Open access112 authors 20 Feb 2023 159
30 Diverse mechanisms of metaeffector activity in an intracellular bacterial pathogen, Legionella pneumophila Malene L. Urbanus, Andrew T. Quaile, P.J. Stogios et al. · Molecular Systems Biology Open access Dec 2016 151
31 Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia Priya Sunil Kishnani, Cheryl R. Greenberg, Frank Rauch et al. · Bone Open access 18 Dec 2018 150
32 ENPP1-Fc prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancy Ronald A. Albright et al. · Nature Communications Open access Dec 2015 146
33 Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome Darin T. Okuda et al. · Annals of Neurology 18 Nov 2022 139
34 Self-assembled phospholipid-based phytosomal nanocarriers as promising platforms for improving oral bioavailability of the anticancer celastrol May S. Freag, Wedad M. Saleh, Ossama Y. Abdallah · International Journal of Pharmaceutics 2 Nov 2017 139
35 Anesthesia for Ophthalmic Surgery in the Elderly MARCO GHIGNONE, Carl Edward Noe, Octavio Calvillo et al. · Anesthesiology Open access May 1988 132
36 Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study Jan Menne, Yahsou Delmas, Fádi Fakhouri et al. · BMC Nephrology Open access 10 Apr 2019 132
37 Protein kinases and phosphatases involved in the acclimation of the photosynthetic apparatus to a changing light environment Jean‐David Rochaix, Sylvain Lemeille, Alexey Shapiguzov et al. · Philosophical Transactions of the Royal Society B Biological Sciences Open access 12 Nov 2012 132
38 Dictionary Learning for Noisy and Incomplete Hyperspectral Images Zhengming Xing, Mingyuan Zhou, Alexey Castrodad et al. · SIAM Journal on Imaging Sciences 2012 130
39 Fairness as partiality aversion: The development of procedural justice Alex Shaw, Kristina R. Olson · Journal of Experimental Child Psychology 27 Nov 2013 130
40 Inducible Costimulator Regulates Th2-Mediated Inflammation, but Not Th2 Differentiation, in a Model of Allergic Airway Disease Amanda G. Tesciuba, Sumit Kumar Subudhi, Russell P. Rother et al. · The Journal of Immunology Aug 2001 129
41 Transfer of a Pathogen from Fish to Amphibians Joseph M. Kiesecker, Andrew R. Blaustein, Cheri L. Miller · Conservation Biology 3 Aug 2001 124
42 PypeIt: The Python Spectroscopic Data Reduction Pipeline Jason Xavier Prochaska et al. · arXiv (Cornell University) PreprintOpen access 7 Apr 2020 123
43 The UPR in atherosclerosis Alex X. Zhou, Ira A. Tabas · Seminars in Immunopathology Open access 3 Apr 2013 122
44 Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes. Litjen Tan, Kenneth B. Gordon, John P. Mueller et al. · PubMed May 1998 119
45 Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria Antonio Maria Risitano, Austin Gladston Kulasekararaj, Jong Wook Lee et al. · Haematologica Open access 29 Oct 2020 113
46 Inhibition of Terminal Complement Components in Presensitized Transplant Recipients Prevents Antibody-Mediated Rejection Leading to Long-Term Graft Survival and Accommodation Hao Wang, Jacqueline Arp, Weihua Liu et al. · The Journal of Immunology Oct 2007 107
47 Significant Role for Fas in the Pathogenesis of Autoimmune Diabetes Xiao Su, Qile Hu, Jane Kristan et al. · The Journal of Immunology Mar 2000 106
48 Effect of Blood Sampling, Processing, and Storage on the Measurement of Complement Activation Biomarkers Shangbin Yang, Michael McGookey, Yi Wang et al. · American Journal of Clinical Pathology 16 Mar 2015 100
49 Presentation of Proteolipid Protein Epitopes and B7-1-Dependent Activation of Encephalitogenic T Cells by IFN-γ-Activated SJL/J Astrocytes Litjen Tan, Kenneth B. Gordon, John P. Mueller et al. · The Journal of Immunology May 1998 96
50 Inalienable Customer Capital, Corporate Liquidity, and Stock Returns Winston Wei Dou, Yan Ji, David J. Reibstein et al. · The Journal of Finance 10 Jul 2020 96

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.